New Approach Uses Modified Stem Cells to Calm Immune Attack in Type 1 Diabetes

Type 1 diabetes occurs when the immune system mistakenly attacks beta cells in the pancreas that produce insulin. This autoimmune attack gradually destroys these cells, leading to insufficient insulin production and high blood sugar. Current treatments focus on managing blood sugar levels, but researchers have long sought ways to stop or slow the immune attack itself—potentially preserving the body's remaining insulin-producing capacity.

A new study published in Diabetes examined whether mesenchymal stem cells (MSCs)—versatile cells capable of many functions—could be engineered to produce more of a protein called PD-L1. This protein acts like a 'brake' on immune responses by signaling T-cells (white blood cells involved in the autoimmune attack) to reduce their activity.

Researchers created PD-L1-overexpressing MSCs and also studied tiny particles these cells release called extracellular vesicles. Both versions were tested to see if they could protect beta cells and slow diabetes development.

The modified stem cells and their released particles produced several measurable effects in laboratory studies: they suppressed T-cell activity, increased the population of regulatory T-cells (immune cells that help prevent autoimmune damage), delayed the onset of diabetes, and reduced the number of immune cells infiltrating the pancreatic islets where beta cells live.

The findings suggest that PD-L1 signaling was central to these protective effects, indicating the engineered protein was doing the intended work of calming immune overactivity.

These laboratory results represent an early but encouraging step toward immune-based therapies for type 1 diabetes. The approach is distinct from current treatments, which manage diabetes symptoms rather than address the underlying immune dysfunction. The fact that both the cells and the particles they release showed benefit offers researchers multiple paths to explore for potential therapies.

However, this research has been conducted in laboratory settings. Much work remains, including testing in animal models and, eventually, determining whether these approaches are safe and effective in people. Anyone interested in participating in future clinical trials should consult their healthcare provider or search clinical trial registries for the most current opportunities.

Source: Diabetes. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.